Search

Displaying results 2371 - 2380 of 10000 in total
  1. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  2. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    It is commonly known as American Trypanosomiasis. … [L15366] The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without symptoms.

  3. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987.

    Mixtures: METİRASİN 1,5 MIU/250 MG FILM TABLET, 14 ADET, METİRASİN 1,5 MIU/250 MG FİLM KAPLI TABLET, 10 ADET
  4. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32024] Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. … FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]

  5. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

  6. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008. … Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.

  7. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition. … Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation.

  8. Drug

    Nazartinib

    go.drugbank.com/drugs/DB16250
    Investigational

    Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating

  9. Drug

    Mupirocin

    go.drugbank.com/drugs/DB00410
    ApprovedInvestigationalVet approved

    [L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes … [L10580] It primarily works by inhibiting bacterial protein synthesis.

    Synonyms: 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acidInternational brands: T-Bact
  10. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair.

    Synonyms: MT-1621 COMPONENT 2'-DEOXYCYTIDINE